Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise
Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.
You may also be interested in...
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
Sandoz Pushes Further Into High-Barrier Generics With $1.5B Acquisition of Fougera
Sandoz is acquiring the U.S. generics dermatology business Fougera, which formerly belonged to Nycomed, for $1.5 billion in cash, giving it entry into a highly profitable niche market.
Nycomed US Crowns New Management; Plans New Direction
Now that Japan's Takeda Pharmaceuticals Co. Ltd. is just months away from closing on its €9.6 billion ($13.7 billion) purchase of privately-held Nycomed AS, the Swiss company's investors are planning plenty of changes for the U.S. dermatology business that wasn’t included in the large acquisition.